Intra Cellular Therapies | ITCI - Ativo Circulante



Ativo Circulante Alterar Data
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
ALKERMES USD 1.36B 570.52M 2026-03
BioCryst Pharmaceuticals USD 373.62M 30.72M 2026-03
Biogen USD 9.19B 216.3M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Cytokinetics USD 839.46M 77.51M 2026-03
Esperion Therapeutics USD 459.46M 3.11M 2026-03
Gilead Sciences USD 18.64B 1.25B 2026-03
Halozyme Therapeutics USD 1B 177.83M 2026-03
J&J USD 59.17B 3.55B 2026-03
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Novartis USD 30.46B 2.26B 2025-12
Prothena USD 339.2M 24.01M 2026-03
RedHill Biopharma USD 12.56M 644K 2025-06
Supernus Pharmaceuticals USD 731.58M 87.4M 2026-03
United Therapeutics USD 2.87B 830.5M 2026-03
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12